FINANCIAL STATEMENTS
An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:
- Balance Sheet
- Income Statement
- Cash Flow Statement
Income Statement
A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.
| Date | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Sep 30, 2024 | Jun 30, 2024 |
|---|---|---|---|---|---|
| reported currency | USD | USD | USD | USD | USD |
| calendar year | 2025 | 2025 | 2025 | 2024 | 2024 |
| period | Q3 | Q2 | Q1 | Q3 | Q2 |
| revenue | 159.933M | 166.496M | 139.292M | 139.494M | 147.026M |
| cost of revenue | 27.991M | 23.002M | 28.662M | 21.021M | 30.142M |
| gross profit | 131.942M | 143.494M | 110.63M | 118.473M | 116.884M |
| gross profit ratio | 0.825 | 0.862 | 0.794 | 0.849 | 0.795 |
| research and development expenses | 216.212M | 164.736M | 165.772M | 170.109M | 152.641M |
| general and administrative expenses | 0 | 0 | 0 | 0 | 0 |
| selling and marketing expenses | 0 | 0 | 0 | 0 | 0 |
| selling general and administrative expenses | 86.62M | 86.646M | 87.797M | 80.351M | 80.604M |
| other expenses | 0 | 0 | 0 | 0 | -1.829M |
| operating expenses | 302.832M | 251.382M | 253.569M | 250.46M | 233.245M |
| cost and expenses | 330.823M | 274.384M | 282.231M | 271.481M | 263.387M |
| interest income | 0 | 5.794M | 6.831M | 10.731M | 7.401M |
| interest expense | 14.148M | 14.041M | 14.342M | 15.712M | 15.96M |
| depreciation and amortization | 8.606M | 8.619M | 8.99M | 8.757M | 8.862M |
| ebitda | -156.786M | -91.344M | -126.438M | -108.744M | -105.918M |
| ebitda ratio | -0.98 | -0.549 | -0.908 | -0.78 | -0.731 |
| operating income | -170.89M | -107.888M | -142.939M | -131.987M | -116.361M |
| operating income ratio | -1.069 | -0.648 | -1.026 | -0.946 | -0.791 |
| total other income expenses net | -8.65M | -6.116M | -6.831M | -1.226M | -14.379M |
| income before tax | -179.54M | -114.004M | -149.77M | -133.213M | -130.74M |
| income before tax ratio | -1.123 | -0.685 | -1.075 | -0.955 | -0.889 |
| income tax expense | 873.00K | 947.00K | 1.31M | 303.00K | 858.00K |
| net income | -180.413M | -114.951M | -151.08M | -133.516M | -131.598M |
| net income ratio | -1.128 | -0.69 | -1.085 | -0.957 | -0.895 |
| eps | -1.808 | -1.17 | -1.57 | -1.40 | -1.52 |
| eps diluted | -1.808 | -1.17 | -1.57 | -1.40 | -1.52 |
| weighted average shs out | 99.771M | 98.46M | 96.289M | 95.494M | 86.581M |
| weighted average shs out dil | 99.771M | 98.46M | 96.289M | 95.494M | 86.581M |
Graph
Balance Sheet
Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.
| Date | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Sep 30, 2024 | Jun 30, 2024 |
|---|---|---|---|---|---|
| reported currency | USD | USD | USD | USD | USD |
| calendar year | 2025 | 2025 | 2025 | 2024 | 2024 |
| period | Q3 | Q2 | Q1 | Q3 | Q2 |
| cash and cash equivalents | 202.51M | 166.106M | 127.055M | 150.619M | 486.865M |
| short term investments | 222.738M | 311.279M | 367.385M | 470.989M | 283.128M |
| cash and short term investments | 425.248M | 477.385M | 494.44M | 621.608M | 769.993M |
| net receivables | 112.543M | 124.464M | 98.839M | 93.301M | 105.982M |
| inventory | 52.20M | 46.498M | 46.031M | 43.334M | 40.137M |
| other current assets | 53.215M | 71.441M | 59.845M | 41.365M | 54.70M |
| total current assets | 643.206M | 719.788M | 699.155M | 799.608M | 964.64M |
| property plant equipment net | 249.961M | 255.763M | 260.906M | 272.448M | 278.707M |
| goodwill | 44.406M | 44.406M | 44.406M | 44.406M | 44.406M |
| intangible assets | 172.943M | 174.733M | 176.524M | 164.942M | 166.243M |
| goodwill and intangible assets | 217.349M | 219.139M | 220.93M | 209.348M | 210.649M |
| long term investments | 22.067M | 51.454M | 68.563M | 203.086M | 114.066M |
| tax assets | 0 | 0 | 0 | 0 | -1.00 |
| other non current assets | 57.862M | 60.121M | 62.373M | 53.873M | 50.375M |
| total non current assets | 547.239M | 586.477M | 612.772M | 738.755M | 653.797M |
| other assets | 0 | 0 | 0 | 0 | 1.00 |
| total assets | 1.19B | 1.306B | 1.312B | 1.538B | 1.618B |
| account payables | 40.573M | 34.242M | 47.45M | 35.99M | 59.807M |
| short term debt | 77.687M | 11.766M | 10.487M | 10.424M | 58.638M |
| tax payables | 0 | 0 | 0 | 0 | 0 |
| deferred revenue | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 221.762M | 247.236M | 233.731M | 238.594M | 154.421M |
| total current liabilities | 340.022M | 293.244M | 291.668M | 285.008M | 272.866M |
| long term debt | 785.426M | 24.531M | 27.786M | 23.657M | 867.898M |
| deferred revenue non current | 0 | 0 | 0 | 0 | 25.741M |
| deferred tax liabilities non current | 0 | 30.058M | 30.058M | 30.058M | 30.058M |
| other non current liabilities | 48.838M | 800.146M | 811.169M | 845.813M | 15.197M |
| total non current liabilities | 834.264M | 854.735M | 869.013M | 899.528M | 913.153M |
| other liabilities | 0 | 0 | 0 | 0 | 0 |
| capital lease obligations | 33.833M | 36.297M | 38.273M | 34.081M | 25.741M |
| total liabilities | 1.174B | 1.148B | 1.161B | 1.185B | 1.186B |
| preferred stock | 0 | 0 | 0 | 0 | 0 |
| common stock | 96.00K | 96.00K | 94.00K | 92.00K | 92.00K |
| retained earnings | -4.403B | -4.223B | -4.108B | -3.823B | -3.69B |
| accumulated other comprehensive income loss | 8.811M | -268.00K | -341.00K | 896.00K | 2.30M |
| other total stockholders equity | 4.404B | 4.374B | 4.252B | 4.169B | 4.12B |
| total stockholders equity | 9.159M | 151.286M | 144.246M | 346.827M | 432.418M |
| total equity | 16.159M | 158.286M | 151.246M | 353.827M | 432.418M |
| total liabilities and stockholders equity | 1.19B | 1.306B | 1.312B | 1.538B | 1.618B |
| minority interest | 7.00M | 7.00M | 7.00M | 7.00M | 0 |
| total investments | 244.805M | 362.733M | 435.948M | 674.075M | 397.194M |
| total debt | 863.113M | 36.297M | 38.273M | 34.081M | 926.536M |
| net debt | 660.603M | -129.809M | -88.782M | -116.538M | 439.671M |
Graph
Cash Flow
A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.
| Date | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Sep 30, 2024 | Jun 30, 2024 |
|---|---|---|---|---|---|
| reported currency | USD | USD | USD | USD | USD |
| calendar year | 2025 | 2025 | 2025 | 2024 | 2024 |
| period | Q3 | Q2 | Q1 | Q3 | Q2 |
| deferred income tax | 0 | 0 | 0 | 0 | 0 |
| stock based compensation | 37.01M | 38.529M | 39.917M | 41.577M | 39.363M |
| change in working capital | 9.735M | -21.814M | -56.633M | 39.661M | 16.358M |
| accounts receivables | 5.425M | -12.653M | 10.062M | 9.792M | 2.158M |
| inventory | -5.595M | 208.00K | -763.00K | -2.50M | -4.127M |
| accounts payables | 0 | -9.682M | -48.454M | 10.818M | 25.329M |
| other working capital | 9.905M | 313.00K | -17.478M | 449.00K | -7.002M |
| other non cash items | 33.639M | 1.733M | -7.669M | 12.808M | 23.779M |
| net cash provided by operating activities | -91.423M | -108.273M | -166.475M | -66.995M | -76.963M |
| investments in property plant and equipment | -1.278M | -2.46M | -1.324M | 10.883M | -4.509M |
| acquisitions net | 0 | 0 | 0 | 7.00M | 0 |
| purchases of investments | 0 | -15.503M | 0 | -367.379M | -3.373M |
| sales maturities of investments | 0 | 89.446M | 136.994M | 93.697M | 68.487M |
| other investing activites | 118.46M | -308.00K | -15.78M | -12.703M | -41.00K |
| net cash used for investing activites | 117.182M | 71.175M | 119.89M | -275.502M | 60.564M |
| debt repayment | 0 | 0 | 0 | 0 | 0 |
| common stock issued | 0 | 83.649M | 0 | -3.84M | 384.881M |
| common stock repurchased | 0 | 0 | 0 | 0 | 58.00K |
| dividends paid | 0 | 0 | 0 | 0 | 0 |
| other financing activites | 2.00K | 0 | 157.00K | 15.014M | 384.939M |
| net cash used provided by financing activities | 2.00K | 83.649M | 157.00K | 11.174M | 384.939M |
| effect of forex changes on cash | 294.00K | 2.914M | 1.448M | 1.275M | -648.00K |
| net change in cash | 26.055M | 49.465M | -44.98M | -326.651M | 368.311M |
| cash at end of period | 214.699M | 188.644M | 139.179M | 160.214M | 486.865M |
| cash at beginning of period | 188.644M | 139.179M | 184.159M | 486.865M | 118.554M |
| operating cashflow | -91.423M | -108.273M | -166.475M | -66.995M | -76.963M |
| capital expenditure | -1.278M | 12.54M | -16.324M | 10.883M | -4.509M |
| free cash flow | -92.701M | -95.733M | -182.799M | -56.112M | -81.472M |
Graph
Frequently Asked Questions
How did Ultragenyx Pharmaceutical Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, RARE generated $159.93M in revenue last quarter, while its costs came in at $27.99M.
Last quarter, how much Gross Profit did Ultragenyx Pharmaceutical Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Ultragenyx Pharmaceutical Inc. reported a $131.94M Gross Profit for the quarter ended Sep 30, 2025.
Have RARE's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. RARE incurred $302.83M worth of Operating Expenses, while it generated -$170.89M worth of Operating Income.
How much Net Income has RARE posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Ultragenyx Pharmaceutical Inc., the company generated -$180.41M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Ultragenyx Pharmaceutical Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Ultragenyx Pharmaceutical Inc. as of the end of the last quarter was $202.51M.
What are RARE's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, RARE had Total Net Receivables of $112.54M.
In terms of Total Assets and Current Assets, where did Ultragenyx Pharmaceutical Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of RARE were $643.21M, while the Total Assets stand at $1.19B.
As of the last quarter, how much Total Debt did Ultragenyx Pharmaceutical Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of RARE's debt was $863.11M at the end of the last quarter.
What were RARE's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, RARE reported total liabilities of $1.17B.
How much did RARE's Working Capital change over the last quarter?
Working Capital Change for RARE was $9.74M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
RARE generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. RARE generated -$91.42M of Cash from Operating Activities during its recently reported quarter.
What was RARE's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. RARE reported a $26.06M Net Change in Cash in the most recent quarter.